CD8A and neoplasm: performed a first in human pilot study assessing the feasibility, safety, and toxicity of intracranial administration of first-generation autologous interleukin-13 receptor subunit alpha-2 (IL13Rα2)-specific CAR CD8+ T cell clones for the treatment of recurrent high-grade glioma (WHO grade III and IV) following tumor resection.